About this Research Topic
The Covid-19 crisis has revealed the strengths of modern drug discovery and vaccine development but also exposed different types of weaknesses that would need to be addressed to be better prepared for a possible next global health crisis. These challenges/weaknesses/obstacles are of very different nature and as such hard to tackle. For instance, in addition to the inherent challenging nature of the scientific discovery, some scientists have mentioned insufficient local/national coordination and observed a fragmented drug discovery research, others have underlined a lack of coordination between the academic system and the private sector, an inadequate international global coordination and cooperation, others highlighted insufficient infrastructures, inappropriate financial supports, limited discussions between the scientific community performing the research and the public health authorities, decision makers and the society, while some remarked insufficient education/training about drug discovery and development leading to confusion… The crisis also raised important scientific questions about the technologies that would need to be used during an emergency situation, combined, integrated, or developed so as to accelerate the identification of small molecule drug candidates and of therapeutic peptides/proteins.
The overall goals of this Research Topic are twofold: (a) discuss anti-Covid-19 chemical probes and drug candidates with a special emphasis on small molecules, peptides and proteins including antibodies and (b) encountered problems in your laboratory, institute, or country… to design/develop these molecules (or move them to the drug development path) as well as suggestions to improve the process at the local, national and/or international levels. This article collection also includes manuscripts describing initiatives that were helpful during the Covid-19 crisis, techniques/strategies utilized or developed in light of some of the above mentioned impediments. The articles reported in this special edition will thus inspire, inform and provide direction and guidance to researchers and public health authorities.
Specifically, topics of interest include, but are not limited to:
- Novel drug candidates, from small molecules to biologics and novel targets/pathways
- Drug repurposing and drug combination
- Main obstacles that impeded the rapid discovery of these molecules
- The technologies/platforms/skills that have been helpful or developed and the ones that were missing or unavailable
- The contribution of artificial intelligence, chemoinformatics, structural bioinformatics, the analysis of electronic health records, experimental and virtual screening, biophysical approaches, animal models including zebrafish studies, organ-on-a-chip… to the discovery or design of these compounds
- Variants and strategies to tackle possible drug resistance
- Translational aspects in the field of infectious diseases
- The possible need of precision medicine to treat some Covid-19 patients
- Covid clinical trial landscape, lessons learned and future plans
- Long Covid, molecular mechanisms and potential treatments
The type of papers accepted in this topic: review, opinion, perspective, original research
Keywords: Drug discovery and development, small molecules, biologics, Covid-19, global health crisis, clinical trials
Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.